Chaugule Sonal S, Park Jennifer, Finger Paul T
Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center; Department of Ophthalmology, The New York Eye and Ear Infirmary of Mt. Sinai, New York, NY, USA.
Department of Ophthalmology, The New York Eye and Ear Infirmary of Mt. Sinai, New York, NY, USA.
Indian J Ophthalmol. 2018 Jan;66(1):55-60. doi: 10.4103/ijo.IJO_590_17.
The purpose of this study is to report on the efficacy and safety of topical chemotherapy alone for giant ocular surface squamous neoplasia (OSSN).
In this retrospective, interventional series, 10 eyes with giant OSSN underwent exfoliative biopsy to confirm the diagnosis followed by application of interferon alpha 2b (IFN α2b) and/or 5 fluorouracil, 1% (5FU). Reported outcome measures were tumor response, visual acuity, recurrence, systemic metastasis, and treatment complications.
Ten patients (3 female, 7 male) had a mean age of 73 (median, 69; range 40-89) years. Mean tumor diameter was 13.1 (median, 12.3; range 8.2-19.4) mm. Five (50%) eyes were treated with IFN-α2b alone; 1 (10%) with 5-FU alone and 4 (40%) required both IFN-α2b and 5-FU. The mean duration of treatment was 3, 0.5, and 6.4 months for IFN-α2b alone, 5-FU alone, and both IFN-α2b and 5-FU respectively. Complete tumor response was observed in all 10 cases at mean follow-up of 12.8 (median, 11.5; range, 3-25) months. Complications noted were transient irritation and burning (n = 4), dry eyes (n = 2), and transient flu-like symptoms (n = 2). There was no evidence of chemotherapy-related symblepharon, stem cell deficiency, scleral thinning, or corneal opacity. There were no tumor recurrences, and no patient required surgical excision or cryotherapy.
Topical chemotherapy was a safe and effective treatment, inducing complete regression in all cases of giant OSSN in this series. There were no sight-limiting complications.
本研究旨在报告单纯局部化疗治疗巨大眼表鳞状细胞瘤（OSSN）的疗效和安全性。
在这个回顾性干预系列研究中，10例患有巨大OSSN的眼睛接受了剥脱性活检以确诊，随后应用α2b干扰素（IFNα2b）和/或1%的5氟尿嘧啶（5FU）。报告的观察指标包括肿瘤反应、视力、复发、全身转移和治疗并发症。
10例患者（3例女性，7例男性）的平均年龄为73岁（中位数为69岁；范围为40 - 89岁）。肿瘤平均直径为13.1毫米（中位数为12.3毫米；范围为8.2 - 19.4毫米）。5只（50%）眼睛仅接受IFN-α2b治疗；1只（10%）仅接受5-FU治疗，4只（40%）眼睛需要同时使用IFN-α2b和5-FU。仅使用IFN-α2b、仅使用5-FU以及同时使用IFN-α2b和5-FU的平均治疗持续时间分别为3个月、0.5个月和6.4个月。在平均12.8个月（中位数为11.5个月；范围为3 - 25个月）的随访中，所有10例均观察到肿瘤完全缓解。观察到的并发症包括短暂性刺激和烧灼感（n = 4）、干眼（n = 2）以及短暂性流感样症状（n = 2）。没有证据表明存在化疗相关的睑球粘连、干细胞缺乏、巩膜变薄或角膜混浊。没有肿瘤复发，也没有患者需要手术切除或冷冻治疗。
局部化疗是一种安全有效的治疗方法，本系列中所有巨大OSSN病例均实现了完全消退。没有导致视力受限的并发症。
